NASDAQ:TPST Tempest Therapeutics Q4 2025 Earnings Report $1.03 -0.02 (-1.90%) As of 04:00 PM Eastern ProfileEarnings HistoryForecast Tempest Therapeutics EPS ResultsActual EPS-$0.62Consensus EPS -$0.62Beat/MissMet ExpectationsOne Year Ago EPSN/ATempest Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ATempest Therapeutics Announcement DetailsQuarterQ4 2025Date3/30/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsTempest Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(10-K) Tempest Therapeutics Earnings HeadlinesTempest Therapeutics Announces Senlang Collaboration to Advance TPST-4003 In Vivo CAR-T Pipeline and Appoints Two New DirectorsAugust 13, 2026 | quiverquant.comQTempest Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 13, 2026 | globenewswire.comYou should know about this by Labor Day — it's killing your retirement.Weiss Ratings' Gavin Magor is warning investors about what he calls Project Pyramid, a policy shift he says threatens retirement savings nationwide. His new expose lays out the risks and the defensive steps investors can take before Labor Day. For a limited time, the full Retirement Defense Kit and Weiss Ratings PLUS membership are available at 79% off, but the discount ends Monday at midnight.September 4 at 1:00 AM | Weiss Ratings (Ad)Tempest Therapeutics: Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-TJuly 21, 2026 | finanznachrichten.deTempest Therapeutics Announces Strategic Partnership with Senlang to Advance TPST-4003 into First-in-Human Study in Autoimmune DiseasesJuly 21, 2026 | quiverquant.comQTempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-TJuly 21, 2026 | globenewswire.comSee More Tempest Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tempest Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tempest Therapeutics and other key companies, straight to your email. Email Address About Tempest TherapeuticsTempest Therapeutics (NASDAQ:TPST) is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies. The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells. Additional preclinical programs aim to block key kinases involved in immune suppression, thereby complementing existing checkpoint inhibitors. Tempest has initiated early‐phase clinical studies in North America and Europe, collaborating with academic and industry partners to evaluate safety, pharmacokinetics, and preliminary efficacy in patients with advanced malignancies. Founded in 2017 and headquartered in Cambridge, Massachusetts, Tempest Therapeutics was established to translate cutting‐edge metabolic and immunological insights into novel oncology treatments. The company’s leadership team combines expertise in drug discovery, clinical development, and regulatory strategy, with decades of experience at both emerging biotechnology firms and large pharmaceutical companies. Tempest is supported by leading life‐science investors and maintains research collaborations to expand its pipeline and accelerate the delivery of new therapies to patients worldwide.View Tempest Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Snowflake’s AI Momentum Is Forcing a Fresh Look at the StockAeroVironment’s $465 Million Army Laser Win Expands Its Counter-Drone OpportunityFB Financial's Southern Expansion and Buybacks Drive Analyst OptimismRetail Earnings Just Exposed a Bigger Divide in the U.S. Consumer EconomyAccelerant’s Take-Private Deal Raises a Bigger Question for Insurance StocksDefense Stocks Are Pulling Back as Their Navy Tailwinds Get StrongerThe Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story Upcoming Earnings Adobe (9/10/2026)Oracle (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
